Immuron Ltd (ASX:IMC) (NASDAQ:IMRN) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle.
The Company currently markets and sells Travelan® for the prevention of travellers’ diarrhoea and has two lead clinical assets. IMM-124E is in Phase 2 clinical trials for NASH, ASH and pediatric NAFLD and IMM-529 is in clinical development for clostridium difficile infections. These products together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market.
E-commerce software by Neto